

1 **Insights into the comorbidity between type 2 diabetes and osteoarthritis.**

2 **Authors**

3 Ana Luiza de S. V. Arruda,^{1,2,4} April Hartley,⁵ Georgia Katsoula,^{1,4} George Davey Smith,⁵ Andrew P.
4 Morris,^{1,6} Eleftheria Zeggini^{1,3,11,12, *}

6 **Affiliations**

7 ¹*Institute of Translational Genomics, Helmholtz Munich, Neuherberg, 85764, Germany*

8 ²*Munich School for Data Science, Helmholtz Munich, Neuherberg, 85764, Germany*

9 ³*TUM school of medicine, Technical University Munich and Klinikum Rechts der Isar, Munich, 81675,
10 Germany*

11 ⁴*Technical University of Munich (TUM), School of Medicine, Graduate School of Experimental Medicine,
12 Munich, 81675, Germany*

13 ⁵*MRC Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN, United Kingdom*

14 ⁶*Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The
15 University of Manchester, Manchester, M13 9PT, United Kingdom*

17 **Authors list footnote**

18 ¹¹ Senior authors

19 ¹² Lead contact

21 **Corresponding authors**

22 eleftheria.zeggini@helmholtz-muenchen.de

24 **Abstract**

25 Multimorbidity is a rising public health challenge with important implications for health management
26 and policy. The most common multimorbidity pattern is for the combination of cardiometabolic and
27 osteoarticular diseases. Here, we study the genetic underpinning of the comorbidity between type 2
28 diabetes and osteoarthritis. We find genome-wide genetic correlation between the two diseases, and
29 robust evidence for association signal colocalization at 18 genomic regions. We integrate multi-omics
30 and functional information to resolve the colocalizing signals, and identify high-confidence effector
31 genes, including *FTO* and *IRX3*, which provide proof-of-concept insights into the epidemiologic link
32 between obesity and both diseases. We find enrichment for lipid metabolism and skeletal formation
33 pathways for signals underpinning the knee and hip osteoarthritis comorbidities with type 2 diabetes,
34 respectively. Causal inference analysis identifies complex effects of tissue-specific gene expression on
35 comorbidity outcomes. Our findings provide insights into the biological basis for the type 2 diabetes-
36 osteoarthritis disease co-occurrence.

38 **Introduction**

39 Multimorbidity is defined as the coexistence of multiple chronic diseases in a single individual [1].
40 Worldwide, over 50% of the population older than 65 years is affected by more than one long-term
41 medical condition simultaneously [2]. Commensurate with the rise in life expectancy and average
42 population age, multimorbidity is an increasing global health challenge. However, the majority of
43 health and drug development research is focused on treating and/or preventing individual diseases,
44 leading to interventions that are currently not optimally designed to assist patients suffering from
45 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
multiple health conditions.

46
47 The most prevalent multimorbidity pattern among women and men is the combination of
48 cardiometabolic and osteoarticular diseases [3], exemplified by the highly prevalent co-occurrence of
49 type 2 diabetes and osteoarthritis [4]. Between 2009 and 2016, approximately one in three adults with
50 prediabetes in the US suffered from arthritis [5]. Osteoarthritis is the most common whole-joint
51 chronic disorder, affecting over 520 million people worldwide [6]. It is a degenerative disorder
52 characterized by a local and systemic low-grade inflammation state, irreversible loss of cartilage, and
53 additional bone formation that results in pain, its most prevalent symptom [7]. Across the globe, type
54 2 diabetes affects over 430 million people and is characterized by elevated blood glucose levels and
55 insulin resistance [6]. Both osteoarthritis and type 2 diabetes are complex diseases influenced by
56 genetic, demographic and lifestyle factors, such as older age and obesity [8].

57
58 The majority of observational studies have reported a positive epidemiological association between
59 type 2 diabetes and osteoarthritis of the hip or knee [4]. In a meta-analysis including 1,040,175
60 patients, the unadjusted odds ratio (OR) for type 2 diabetes in osteoarthritis patients compared to
61 non-osteoarthritis patients was 1.41 (95% confidence interval (CI)=[1.21, 1.65]) [9]. For type 2 diabetes
62 patients, the overall risk of osteoarthritis was also higher compared to individuals without type 2
63 diabetes (unadjusted OR=1.46, 95%CI=[1.08, 1.96], N=32,137) [9]. Articular joint-specific analyses
64 have shown a stronger link between type 2 diabetes and knee osteoarthritis than hip osteoarthritis
65 [9].


66
67 Mendelian randomization analyses [10] suggest no causal relation between liability to type 2 diabetes
68 and knee osteoarthritis [11], whereas body-mass index (BMI) has been shown to be causal for both
69 diseases [12], [13]. When adjusting for BMI, studies linking type 2 diabetes and osteoarthritis have
70 yielded conflicting results [4], [9], [14]. Considering that obesity is a major risk factor for both diseases
71 studied here, genetic variants associated with different physiological characteristics of increased
72 adiposity are expected to be shared risk variants for the comorbidity. However, those variants could
73 exert their effects on the comorbidity through alternative biological pathways to obesity through
74 horizontal pleiotropy [10].

75
76 Given the increase of the world's elderly population and the chronic nature of this highly prevalent
77 pair of diseases, understanding their shared genetic background is important in order to identify risk
78 variants and effector genes that could be used as biomarkers or druggable targets for bilateral
79 treatment. Here, we perform a systematic overlap analysis on a genome-wide scale to disentangle the
80 shared genetic aetiology of the type 2 diabetes-osteoarthritis comorbidity, including integration with
81 functional genomics data in relevant cell types, and provide insights into common underpinning
82 mechanisms of disease development, including but not limited to, adiposity.

83 Results


84 Insights into disease biology and treatment targets

85 We first assessed the genetic correlation between type 2 diabetes ($N_{cases} = 74,124$, $N_{controls} =$
86 $824,006$) and osteoarthritis (knee: $N_{cases} = 62,497$, $N_{controls} = 333,557$; hip: $N_{cases} = 36,445$,
87 $N_{controls} = 316,943$) on a genome-wide scale using data from the largest GWAS meta-analyses to
88 date (Table S1 and Figure S1). In line with epidemiological evidence, we find greater magnitude of
89 genetic correlation between type 2 diabetes and knee osteoarthritis ($r^2=0.241$, $SE=0.028$, $p=2.65e-18$)
90 compared to osteoarthritis of the hip ($r^2=0.078$, $SE=0.029$, $p=0.008$) (Figure 1A). To assess the
91 potential for bias due to overlapping samples and different sample sizes, we also performed a
92 permutation-based analysis (empirical p-value for knee=0.005, empirical p-value for hip=0.142)
93 (Figure 1B, Table S1 and Figure S2). Causal inference analyses using Mendelian randomization showed
94 evidence for a non-causal relationship between the two diseases (Table S6), consistent with smaller-
95 scale studies in the literature [12].



96
97 **Figure 1: Stronger evidence for a genetic correlation between type 2 diabetes and knee osteoarthritis compared to hip**
98 **osteoarthritis.** A) Genetic correlation results between type 2 diabetes (T2D) and knee or hip osteoarthritis (OA). B)
99 Permutation-based testing results for knee OA and hip OA, respectively. The red line is the true correlation.


100 Using pairwise Bayesian colocalization analyses on genome-wide significant regions for osteoarthritis
101 ($P = 1.3 \times 10^{-8}$) or type 2 diabetes ($P = 5 \times 10^{-8}$), we found robust evidence (posterior probability \geq
102 0.8) for a shared causal signal between both diseases at 18 genomic loci (Table S2 and Figures S5-S22).
103 Ten of those loci colocalize with type 2 diabetes for both hip and knee osteoarthritis, two colocalize
104 for hip osteoarthritis only, and six colocalize only for knee osteoarthritis. In three genomic loci, the
105 95% credible set for the causal variant from the colocalization analysis consisted of a single variant
106 (Figure 2).
107



108

109 **Figure 2: Overview of colocalizing regions.** The y-axis depicts the posterior probability of a shared causal variant (PP4) and
 110 the x-axis the number of variants in the 95% credible set for the causal variant. Each point represents a colocalized signal
 111 between type 2 diabetes and one osteoarthritis (OA) phenotype. Point size is proportional to the number of variants in the
 112 colocalization analysis 95% credible set. We find strong statistical evidence for colocalization ($PP4 > 0.8$) at 18 unique genomic
 113 loci. Some of those loci colocalize between type 2 diabetes and more than one osteoarthritis phenotype, thus we have 51
 114 points.

115 We incorporated multi-omics and functional information to identify shared high-confidence candidate
 116 effector genes for the type 2 diabetes-osteoarthritis comorbidity in the colocalizing loci. Twelve of
 117 these showed statistical evidence for colocalization with gene expression or protein quantitative trait
 118 loci (eQTLs and pQTLs, respectively) from disease-relevant tissues (cartilage chondrocytes,
 119 synoviocytes and/or pancreatic beta cells). In total, we analysed 906 genes in the vicinity of
 120 colocalizing genomic regions by integrating six lines of complementary evidence (Figure 3 and Table
 121 S3).
 122



123

124 **Figure 3: Study design.** In each of the 18 genomic loci that colocalized with a posterior probability of a single shared causal
 125 variant ($PP4 \geq 0.8$), we explored all genes in a 1Mb window on either side of the lead variants of the 95% credible set for the
 126 causal variant of the colocalization analysis. For each gene, we searched databases for knockout mice, and rare and syndromic
 127 human diseases for pre-defined type 2 diabetes- and musculoskeletal-related phenotypes. We also examined differentially
 128 expressed genes (DEGs) in pancreatic islets of healthy versus diabetes patients, and of degraded versus intact osteoarthritis
 129 cartilage. We examined the variants in the 95% credible set for the causal variant of each colocalization locus for missense
 130 variants. We performed regional multi-trait colocalization analyses between type 2 diabetes, each osteoarthritis phenotype,
 131 and molecular QTL (gene expression and protein QTL) from disease-relevant tissues. We also examined previously curated
 132 high-confidence effector genes for type 2 diabetes or osteoarthritis (Methods).

133 We defined 72 genes as likely effector genes for the type 2 diabetes-osteoarthritis comorbidity, as
134 they displayed at least one line of supporting evidence for being involved in both diseases. Of the 72
135 likely effector genes, 19 showed at least three lines of evidence and were defined as high-confidence
136 effector genes (Figure 4). These represent relevant candidates for further functional and clinical
137 research. Eleven of these have not previously been defined as high-confidence genes for either
138 disease. For two of the high-confidence genes, *APOE* and *WSCD2*, the 95% credible set for the causal
139 variant from the colocalization analysis includes missense variants, namely rs429358 and rs3764002.
140 Six out of 19 high-confidence effector genes are the nearest gene to the lead variant of the respective
141 colocalizing genomic locus: *WSCD2*, *TCF7L2*, *JADE2*, *GLIS3*, *FTO* and *APOE* (Figure S3).

142
143 We searched the druggable genome for the druggability status of the likely effector genes for the type
144 2 diabetes and osteoarthritis comorbidity [15]. Sixteen out of 72 genes were included in the druggable
145 genome (Table S4). Of these, 6 genes are tier 1 druggable targets (*GIPR*, *TPO*, *PAK1*, *SIGMAR1*, *CTSB*,
146 *NOS3*), i.e., they are targets of drugs that have market authorization or are in clinical development.
147 The *GIPR* agonist tirzepatide was recently approved for the treatment of type 2 diabetes in adults. It
148 has glucose-lowering effects and has been shown to increase insulin sensitivity [16]. The *PAK1*
149 inhibitor fostamatinib has been approved for the treatment of chronic immune thrombocytopenia
150 [17]. It is also in clinical trial for the treatment of rheumatoid arthritis in order to alleviate the degree
151 of inflammation of the joints [18]. *SIGMAR1* is a target of multiple approved drugs, including
152 pentazocine, which is an analgesic used to treat moderate to severe pain. Naltrexone, an antagonist
153 used in opioid overdose that also targets *SIGMAR1*, is being investigated for treating obesity [19], [20].
154 The *TPO* gene encodes the thyroid peroxidase protein, which is the target of several approved drugs
155 for the treatment of hyperthyroidism. One of these, the thyroid hormone dextrothyroxine, has been
156 shown to lower serum levels of cholesterol in humans, but the interventional study has been
157 discontinued due to serious adverse effects [21].

158
159 The 72 likely effector genes were enriched for several metabolic and cellular process, and for lipid
160 localization and storage pathways. Hip osteoarthritis-related likely effector genes were enriched for
161 bone development pathways and metabolic processes. The 19 high-confidence effector genes were
162 enriched for biological pathways related to diet and obesity (response to caloric restriction and Fto
163 obesity variant mechanism) and for regulation of cell differentiation. The high-confidence genes
164 related to hip osteoarthritis were enriched for the Fto obesity variant mechanism pathway, regulation
165 of lipid localization, and for a biological pathway related to skeletal formation (proximal/distal pattern
166 formation) (Table S5 and Figure S4). These results provide biological support for the link between
167 obesity and both diseases, and for the association between bone development and hip osteoarthritis
168 [7].

169


170 [Disentangling the effect of obesity](#)

171 To explore the role of obesity on the co-occurrence of type 2 diabetes and osteoarthritis, we studied
172 four different measures that capture different aspects of obesity and adiposity: BMI, waist-to-hip
173 ratio, whole body fat mass, and body fat percentage. Sixteen out of the 18 genomic regions that
174 colocalized between type 2 diabetes and osteoarthritis show evidence of association or colocalization
175 ($PP4 > 0.8$) with at least one adiposity-related trait (Table S9). Four high-confidence effector genes
176 reside in the two genomic regions that do not show any evidence of colocalization or association with
177 the analysed measures of adiposity: *TMEM176A*, *RARRES2*, *SMARCD3* and *GLIS3*. These may point to
178 alternative biological mechanisms other than adiposity in the comorbidity between type 2 diabetes
179 and osteoarthritis for these colocalizing signals.

180 We investigated whether these adiposity measures were causally associated to the expression of high-
181 confidence effector genes in disease-relevant tissues. Within the constraints of the available
182 instruments (Methods), we found evidence of a causal relationship between several adiposity

183 measures and nine high-confidence effector genes (Table S7). For example, we find that all measures
184 of adiposity have a causal effect on higher expression of *IRX3* in synovium or pancreatic islets and on
185 lower expression of *RTN2* in osteoarthritis cartilage. For the high-confidence effector genes located in
186 the two genomic loci that did not show evidence of association or colocalization with adiposity, the
187 direction of effect was not consistent across the different measures employed.

188 We assessed the causal role of BMI-associated variants with tissue-specific effects, selected based on
189 evidence of their colocalization with brain or subcutaneous adipose tissue eQTLs [22]. For type 2
190 diabetes, we replicated previous results and showed that BMI-associated variants influencing genes
191 expressed in brain tissue exert a stronger effect on the disease than adipose-tissue related variants
192 [22], although confidence intervals largely overlapped. For knee osteoarthritis, we observed the same
193 trend (Figure S23). For hip osteoarthritis, the results of the causal inference analysis provide evidence
194 for a stronger effect of BMI-associated variants that colocalize with adipose-tissue eQTLs than with
195 brain eQTLs (Table S10). Our results suggest a similar biological underpinning of the adiposity effect
196 captured by BMI on type 2 diabetes and knee osteoarthritis, but potentially different processes for
197 hip osteoarthritis.



198
199
200
201
202

Figure 4: Overview of the 19 high-confidence effector genes for the type 2 diabetes and osteoarthritis comorbidity. Genes are stratified based on the joint affected by osteoarthritis. The scoring of the six biological lines of evidence is depicted on the right (Methods.) (OA = osteoarthritis; T2D = type 2 diabetes; molQTL = molecular quantitative trait loci; DEG = differential

203 *expressed genes; KO mice = knockout mice; OMIM = Online Mendelian Inheritance in Man; HC = previously defined high-*
204 *confidence effector genes; missense = missense variant).*

205 Insights gained from individual loci

206 *FTO* and *IRX3*

207 The obesity-related *FTO* locus colocalizes for type 2 diabetes and osteoarthritis with a posterior
208 probability of a shared causal variant of over 92% (Figure 5). The 95% credible set from the
209 colocalization analysis consists of multiple variants in high linkage disequilibrium with each other. The
210 risk-increasing alleles for the lead causal variants are the same across type 2 diabetes and
211 osteoarthritis. In addition to *FTO*, this locus is associated with a further high-confidence effector gene,
212 *IRX3*. *IRX3* eQTLs in pancreatic islets colocalize with type 2 diabetes and osteoarthritis genetic signals
213 with a PP4 > 0.8.

214

215 As shown above, adiposity is causally associated with an increase in *IRX3* expression in pancreatic islets
216 and synovium (Table S7A). Here, we performed causal inference analyses between the expression of
217 high-confidence genes at this locus and type 2 diabetes or osteoarthritis. We find evidence for a causal
218 effect of increased expression of *IRX3* in pancreatic islets on increased risk of type 2 diabetes (OR=1.16;
219 95%CI=[1.08, 1.25]; p-value=4.4E-05, F-stat= 16.7).

220 *FTO* is a high-confidence osteoarthritis effector gene involved in skeletal development, adipogenesis,
221 and neuronal function and development [23]. It is also associated with syndromic human disease
222 *growth retardation, developmental delay, and facial dysmorphism (GDFD)*, which is a lethal autosomal
223 recessive multiple congenital anomaly syndrome [24]. *IRX3* is a known functional long-range target of
224 *FTO* variants associated with obesity [25]. *FTO* and *IRX3* knockout mice show decreased body weight,
225 decreased bone mineral density, and improved glucose tolerance (high bone mineral density is a risk
226 factor for hip and knee osteoarthritis [26]). We expected genes with an adiposity-driven effect to be
227 involved in the shared genetic aetiology of the type 2 diabetes-osteoarthritis comorbidity since obesity
228 constitutes a common risk factor [8].

229

230 *TCF7L2*

231 *TCF7L2* is one of the highest-scoring effector genes. This genomic locus colocalizes for type 2 diabetes
232 and knee osteoarthritis with a posterior probability of a shared causal variant of over 93% (Figure 5).
233 Here, the 95% credible set for the causal variant from the colocalization analysis consists of three
234 variants, which have opposite risk-increasing alleles for type 2 diabetes and knee osteoarthritis (Table
235 S8A). *TCF7L2* has not been associated with osteoarthritis at genome-wide significance levels to date
236 (all variants in the credible set achieve nominal significance in the latest knee osteoarthritis GWAS
237 [23]). Genetic variants associated with *TCF7L2* expression in pancreatic islets and in osteoarthritis
238 cartilage colocalize with this association signal. For the variants in both 95% credible sets from these
239 colocalization analyses, the risk-increasing alleles for type 2 diabetes are associated with a lower BMI,
240 a lower risk of knee osteoarthritis and an increased expression of *TCF7L2* in pancreatic islets and
241 osteoarthritic cartilage.

242

243 We find evidence that increased BMI causes decreased expression of *TCF7L2* in intact and degraded
244 cartilage (Table S7A). Additionally, we find evidence that an increase in *TCF7L2* expression in
245 pancreatic islets causes an increase in type 2 diabetes risk (OR=5.1; 95%CI=[4.7, 5.4]; p-value<1E-300;
246 F-stat=2018) and a decrease in knee osteoarthritis risk (OR=0.83; 95%CI=[0.77, 0.91]; p-value=1.77E-
247 05; F-stat=18.4). These results are in line with the evidence shown above in support of an opposite
248 effect of the genetic variants associated with the expression of *TCF7L2* in knee osteoarthritis and type
249 2 diabetes risk.

250 *TCF7L2* is among the leading signals for type 2 diabetes risk, persisting following adjustment for BMI
251 [27]. Our results suggest that *TCF7L2* exerts an effect that goes through an alternative biological
252 pathway to increased BMI. It has been shown that isoforms of *TCF7L2* regulate the expression of genes
253 related to cartilage destruction in human chondrocytes [28]. *TCF7L2* is a key effector gene of the
254 Wnt/ β -catenin signalling pathway. This pathway plays a role in both type 2 diabetes, through glucose
255 homeostasis, and in osteoarthritis, through cartilage and bone formation [29], [30].

256

257 *TMEM119* and *WSCD2*

258 Two high-confidence effector genes, *WSCD2* and *TMEM119*, reside in the same genomic locus, which
259 colocalizes for type 2 diabetes and knee osteoarthritis with a posterior probability of 99.9% (Figure 5).
260 The 95% credible set consists of two variants: rs1426371 and rs3764002, an intronic and a missense
261 variant (amino acid change: Thr266Ile) within *WSCD2*, respectively. The risk-increasing alleles of both
262 variants are concordant for osteoarthritis of the knee and type 2 diabetes. The variant with the highest
263 posterior probability of being causal for osteoarthritis and type 2 diabetes, rs1426371, has reached
264 genome-wide significance levels in the latest knee osteoarthritis GWAS meta-analysis [23]. The
265 missense variant, rs3764002, is associated with BMI, type 2 diabetes, lean mass, and neuropsychiatric
266 disorders including anxiety and schizophrenia. The missense variant is predicted to alter protein
267 function and this alteration is predicted to be damaging by both SIFT (<https://sift.bii.a-star.edu.sg>) and
268 PolyPhen (<http://genetics.bwh.harvard.edu/pph2/>).

269

270 *WSCD2* eQTLs in degraded osteoarthritis cartilage colocalize with type 2 diabetes and knee
271 osteoarthritis with a posterior probability of 99%. The lead eQTLs are rs142637 and rs3764002. The
272 expression level-increasing alleles are the same as the risk-increasing alleles for both diseases (Table
273 S8B). *WSCD2* is also a differentially expressed gene (DEG) in pancreatic islets from diabetes patients
274 versus healthy controls and is downregulated in diabetic islets. Moreover, it has been previously
275 shown that *WSCD2* is functionally associated with type 2 diabetes and positively correlated to insulin
276 secretion [31],[32]. Conclusions from causal inference analysis were limited due to weak instruments
277 (F-statistic<10), which can bias causal effect inference (Table S7). Further research is needed to better
278 understand the biological mechanisms through which *WSCD2* influences the type 2 diabetes-
279 osteoarthritis comorbidity.

280

281 *TMEM119* is the second most highly scoring high-confidence effector gene. It is a DEG in osteoarthritis
282 cartilage and pancreatic islets and is more highly expressed in degraded compared to intact cartilage
283 and in healthy compared to pancreatic islets. Knockout mice for *TMEM119* show phenotypes related
284 to both osteoarthritis and type 2 diabetes, such as decreased body weight, impaired osteoblast
285 differentiation, and decreased compact bone thickness. *TMEM119* is related to bone formation by
286 promoting osteoblast differentiation [33]. Fewer osteoblasts can lead to a decrease in compact bone
287 thickness, which is also observed in knockout mice [34]. The over-expression of *TMEM119* in degraded
288 cartilage from osteoarthritis patients supports the evidence of an increase in bone formation in later
289 stages of the disease [35]. However, the lower expression of *TMEM119* in diabetes compared to
290 healthy pancreatic islets points to further potential mechanisms of effect in the comorbidity.

291


292 *TMEM176A*

293 *TMEM176A*, also a high-confidence effector gene, has not been previously identified as implicated in
294 either osteoarthritis or type 2 diabetes. This locus colocalizes for type 2 diabetes and knee
295 osteoarthritis with a posterior probability of a shared causal variant of 99.3% (Figure 5). The index
296 variants are rs62492368 and rs7794796, both located in the intron of the *AOC1* gene. rs62492368 is
297 associated with type 2 diabetes [36] and rs7794796 is associated with appendicular lean mass [37].
298 Type 2 diabetes and osteoarthritis show opposite risk-increasing alleles for all variants in the 95%
299 credible set from the colocalization analysis (Table S8C). These variants colocalize with PP4 > 0.8

300 between the diseases and eQTL data from pancreatic islets and synovium. The index variants from the
301 colocalization with eQTLs also have opposite risk-increasing alleles for both diseases. Similarly, to the
302 *TCF7L2* locus case, our results suggest that the mechanism through which *TMEM176A* exerts an effect
303 on osteoarthritis and type 2 diabetes may have contrary directions.

304
305 We found body fat percentage to be linked to a decrease in the expression of *TMEM176A* in synovium
306 (Table S7A), albeit with weak instruments (F-statistic<10). Decreased expression of *TMEM176A* in
307 intact osteoarthritis cartilage and pancreatic islets was associated with reduced risk of type 2 diabetes
308 (pancreatic islets: OR=1.14, 95%CI=[1.07, 1.21], p-value=8.5E-05, F-stat=15.4; cartilage: OR=1.05,
309 95%CI=[1.03, 1.08], p-value=8.5E-05, F-stat=15.4) and increased risk of knee osteoarthritis (pancreatic
310 islets: OR=0.93; 95%CI=[0.87, 0.99]; p-value=0.048; F-stat=3.9, cartilage: OR=0.97; 95%CI=[0.94, 0.99];
311 p-value=0.048; F-stat=3.9). This genomic locus is one of the two colocalizing regions that do not show
312 any evidence of statistical colocalization between type 2 diabetes, osteoarthritis and the adiposity
313 measures studied here. This suggests that this region, and possibly *TMEM176A*, acts through an
314 alternative biological path to adiposity.

315
316 Results of the causal inference analysis mirror the output of differential expression analyses
317 conducted in pancreatic islets and osteoarthritic cartilage [38], [39]. While *TMEM176A* is more highly
318 expressed in diabetes compared to healthy pancreatic islets, an increase of its expression in the same
319 tissue has a causal effect on increased risk of type 2 diabetes. Similarly, while *TMEM176A* was found
320 to have lower expression in degraded compared to intact cartilage, the reduced expression of this
321 gene in intact cartilage has a causal effect on increased risk of total knee replacement.



322
 323 **Figure 5: Regional association plots of the highlighted colocalizing regions between type 2 diabetes and osteoarthritis. a)**
 324 **FTO and IRX3 region; b) TCF7L2 region; c) WSCD2 and TMEM119 region; d) TMEM176A region. The plots are colored based**
 325 **on linkage disequilibrium between the lead causal variant and all other variants. (PP4 = posterior probability of a single**
 326 **shared causal variant; OA = osteoarthritis; T2D = type 2 diabetes; All OA = osteoarthritis at any site)**

327 Discussion

328 We present an approach to disentangle the shared genetic aetiology between two co-occurring
 329 chronic diseases, exemplified through the type 2 diabetes-osteoarthritis comorbidity. Studies have
 330 shown a stronger association of BMI with osteoarthritis of the knee than of the hip [12]. We find

331 stronger statistical evidence of a genetic correlation between type 2 diabetes and knee osteoarthritis
332 compared to hip osteoarthritis. By leveraging the latest large-scale GWAS for both diseases, we find
333 robust evidence of colocalization at 18 genomic loci and, by incorporating multi-omics and functional
334 genomics information, we derive a list of 19 high-confidence effector genes for the comorbidity. The
335 majority of genomic loci colocalize for type 2 diabetes and knee, rather than hip, osteoarthritis, in
336 keeping with the genome-wide correlation analysis results.

337
338 Our findings support the epidemiological link between obesity, osteoarthritis, and type 2 diabetes. In
339 this case, only two of the 18 colocalized regions do not colocalize with measures of adiposity. Several
340 of the high-confidence genes are associated with obesity-related traits, including *FTO* and *IRX3*. We
341 show that the identified high-confidence effector genes are enriched for biological pathways
342 associated with adiposity. Stratifying the high-confidence effector genes into knee or hip osteoarthritis
343 provides further insight into the biological mechanisms underlying the comorbidity. High-confidence
344 effector genes mostly related to hip osteoarthritis are also enriched for biological pathways of skeletal
345 formation, which underlines the strong link between bone development and hip osteoarthritis [7].
346 Given that two-thirds of FDA-approved drugs are supported by genetic evidence, we explore the
347 druggable potential of the prioritized genes [40]. We highlight approved drugs currently used for the
348 treatment of diabetes, obesity, pain, and inflammation.

349
350 Observational studies report that the positive association between type 2 diabetes and osteoarthritis
351 persists after adjusting for BMI [9]. As BMI only captures a limited subset of the effect of adiposity on
352 the comorbidity, this could be a source of residual confounding due to measurement error [41] and
353 observed attenuation of association can be underestimated. We performed in-depth analyses to
354 disentangle the role of adiposity on the comorbidity and find evidence that *TCF7L2* and *TMEM176A*
355 exert an effect on type 2 diabetes and osteoarthritis through an alternative biological path. Further
356 examination, including functional studies, is needed to dissect the precise way in which these genes
357 affect the comorbidity.

358
359 Type 2 diabetes and insulin resistance are known to be negatively correlated with bone strength and
360 are also associated with bone fracture [42]. One possible link between bone and lipid metabolism is
361 the fact that osteoblasts and adipocytes share a common progenitor cell in adult bone marrow with a
362 degree of plasticity that can lead to an imbalance between the two cell lineages [43]. In support of
363 this link, differentiation regulation of osteoblasts is highlighted by one of the identified high-
364 confidence effector genes, *TMEM119*. In summary, we highlight three potential biological
365 mechanisms underpinning the comorbidity between type 2 diabetes and osteoarthritis: obesity,
366 imbalance between osteoblasts and adipocytes differentiation in adult bone marrow and the Wnt/ β -
367 catenin signalling pathway.

368
369 The genetic and functional genomic data employed in this study are biased towards European
370 populations. Going forward, it will be important to expand analyses to data from diverse populations.
371 The eQTL data from pancreatic islets used in the analyses here comprise almost four times as many
372 samples as the eQTL data from chondrocytes. Therefore, molecular QTL analyses for type 2 diabetes-
373 relevant tissues were better-powered than for osteoarthritis-relevant tissues. Mendelian
374 randomization and the subsequent sensitivity analyses were conducted within the constraints of
375 available instruments for expression of the high-confidence genes. This was partially because the
376 molecular QTL data used in this work include cis-QTLs only, which restricts the analyses to variants
377 within the vicinity of the genes or proteins of interest. Future studies should include a wider array of
378 (as yet unavailable) genome-wide molecular QTLs, including at the single-cell level.

379
380 We have studied one of the most frequently co-occurring pairs of complex diseases: type 2 diabetes
381 and osteoarthritis. Our findings offer insights into the biological processes underpinning the

382 comorbidity and highlight potential drug repurposing opportunities in addition to new targets. As the
383 world population life expectancy continues on an upward trajectory, the challenge of tackling
384 multimorbidity will continue to be high on the healthcare agenda. Genomic data-based approaches,
385 as exemplified here for type 2 diabetes and osteoarthritis, can help improve our understanding of the
386 co-occurrence of chronic conditions.

387

388 Acknowledgements

389 We thank Lorraine Southam and Konstantinos Hatzikotoulas for their input and support. We also
390 thank the Genetics of Osteoarthritis (GO), the DIAMANTE and the InsPIRE consortia for providing their
391 data.

392

393 Author contributions

394 E.Z. and A.L.S.V.A conceived and designed the study and wrote the manuscript. A.L.S.V.A and A.H.
395 performed computation and statistical analyses and produced the figures. A.L.S.V.A, G.D.S, A.H., E.Z.
396 and A.P.M. performed data interpretation. A.L.S.V.A, G.D.S, A.H., E.Z. G.K, and A.P.M. provided
397 significant feedback on the methods, results, and manuscript.

398

399 Declaration of interest

400 A.H. and G.D.S. work in a unit funded by the Medical Research Council (MRC) and the University of
401 Bristol (MC_UU_00011/1, MC_UU_00011/3). The remaining authors declare no competing interests.

402

403 Data and code availability

- 404 • This paper analyzes existing, publicly available data. These accession numbers for the datasets
405 are listed in the key resources table.
- 406 • All original code has been deposited at Zenodo and is publicly available as of the date of
407 publication. DOIs are listed in the key resources table.
- 408 • Any additional information required to reanalyze the data reported in this paper is available
409 from the lead contact upon request.

410

411 Methods

412 Resource availability

413 Lead contact

414 Further information requests should be directed to the lead contact, Eleftheria Zeggini
415 (eleftheria.zeggini@helmholtz-muenchen.de).

416 Materials availability

417 This study did not generate new unique reagents.

418 Data and code availability

- 419 • This paper analyzes existing, publicly available data. These accession numbers for the datasets
420 are listed in the key resources table.

- 421 • All original code has been deposited at Zenodo and is publicly available as of the date of
422 publication. DOIs are listed in the key resources table.
423 • Any additional information required to reanalyze the data reported in this paper is available
424 from the lead contact upon request.

425

426 [Methods details](#)

427 [Datasets](#)

428 For osteoarthritis, we used the largest GWAS meta-analysis to date, from the Genetics of
429 Osteoarthritis (GO) consortium [23]. In total, it comprises data from 826,690 individuals (177,517
430 cases) from mostly white European ancestry for 11 different osteoarthritis phenotypes. In this study,
431 we used following osteoarthritis phenotypes: knee, hip, knee and/or hip, total knee replacement
432 (TKR), total hip replacement (THR), total joint replacement (TJR), and osteoarthritis at any site (all). A
433 table with the number of cases, controls, and the total patients for each study can be found in Table
434 1. For type 2 diabetes, the GWAS meta-analysis unadjusted for BMI from the DIAMANTE consortium
435 was used [36]. It includes data from 898,130 individuals (74,124 cases) of European ancestry.
436

OA phenotype	Cases	Controls	Total
All	177,517	649,173	826,690
Knee	62,497	333,557	396,054
Knee and/or hip	89,741	400,604	490,345
Hip	36,445	316,943	353,388
TKR	18,200	233,841	252,041
TJR	40,887	327,689	368,576
THR	23,021	296,016	319,037

437 *Table 1: an overview of osteoarthritis phenotypes used in this work and the number of cases, controls and the total number*
438 *of patients included in the corresponding GWAS.*

439 We also employed molecular QTL data from disease-specific tissues. For osteoarthritis, we used eQTL
440 data from intact cartilage (n=95), degenerated cartilage (n=87) and synovium (n=77), as well as pQTL
441 data from intact and degenerated cartilage (n=99) [44]. All samples were collected from osteoarthritis
442 patients. For type 2 diabetes, we used eQTL data from pancreatic islets from the InsPIRE consortium
443 [45]. In the pancreatic islets data set, 37 patients out of 420 were diabetic.
444 We aligned the effect alleles of all data sets used in this paper by inverting the sign of the effect sizes
445 when a mismatch was detected. Chromosome X was not included in any analysis. All data sets used
446 the Genome Reference Consortium Human Build 37 (GRCh37) assembly.
447

448 [Measures of adiposity](#)

449 We used four measures of adiposity: body mass index (BMI), waist-to-hip ratio (WHR) unadjusted for
450 BMI, whole body fat mass and body fat percentage. For BMI (N=806,834) and WHR (N=697,734), we
451 used the latest meta-analysis combining data from the GIANT consortium and the UK biobank [54].
452 The inverse rank normalized GWAS summary statistics for whole body fat mass (N=330,762) and body
453 fat percentage (N=331,117) were taken from the Neale's Lab website (<http://www.nealelab.is/uk-biobank/>). For each adiposity phenotype, we looked up the effect and significance of all variants in the
454 95% credible set of the colocalized regions between type 2 diabetes and osteoarthritis (Table S9).
455
456

457 [Quantification and statistical analysis](#)

458 [Genetic overlap of type 2 diabetes and osteoarthritis phenotypes](#)

459 We conducted a linkage disequilibrium (LD) score regression analysis using the LDSC software (v1.0.1)
460 with `-rg` flag to estimate the genetic correlation between each osteoarthritis phenotype and type 2

461 diabetes (Table S1) [46]. Since the majority of the GWAS used here comprises data of European
462 ancestry individuals only, pre-computed LD scores from the 1000 Genomes European ancestry
463 haplotypes were used [47]. To assess the potential for chance findings when performing multiple
464 statistical analyses, we performed a permutation-based analysis. We randomly permuted the effects
465 (Z-scores) of the variants for the osteoarthritis phenotypes ten thousand times while fixing the effects
466 for type 2 diabetes. Running LD score regression on each permuted data set yielded an empirical p-
467 value for the genetic correlation of type 2 diabetes and each analysed osteoarthritis phenotype.
468

469 Statistical colocalization analysis

470 We defined regions of 2 Mb (+- 1 Mb) around established independent association signals from each
471 disease. For type 2 diabetes, we selected all primary and secondary independent signals from the BMI
472 unadjusted GWAS (p-value threshold = 5×10^{-8}). For osteoarthritis, we selected the risk signals for the
473 respective phenotype at the adjusted genome-wide significance of 1.3×10^{-8} . For each osteoarthritis
474 phenotype, we performed regional pairwise statistical colocalization analysis with type 2 diabetes
475 using the *coloc.abf* function from the *coloc* R package (version 3.2.1) [48]. Colocalization analyses were
476 conducted using estimated regression coefficients (effect sizes) and standard errors (Table S2). In
477 short, this function calculates posterior probabilities for five association configurations under the
478 assumption of a single causal variant per trait. These configurations are summarized in the hypotheses
479 below:

- H0:** no trait has a genetic association in the region
- H1:** trait 1 has a genetic association in the region
- H2:** trait 2 has a genetic association in the region
- H3:** both traits have a genetic association in the region, but with different causal variants
- H4:** both traits share a genetic association (single causal variant) in the region

480
481 For all osteoarthritis phenotypes, we used the default prior probabilities of the *coloc* R package. We
482 considered evidence for colocalization if the posterior probability of H4 (PP4) > 0.8. For each genomic
483 locus of colocalization, we calculated a 95% credible set for the causal variant by taking the cumulative
484 sum of the variants' posterior probabilities to be causal conditional on H4 being true. LD between the
485 single nucleotide polymorphisms (SNPs) was calculated using plink (version 2.0 alpha) [49] based on
486 the UK biobank [50] and was used for visualizing the results in regional association plots.
487

488 Knockout mouse phenotypes

489 We performed a schematic search for each gene in the vicinity of the colocalized genomic loci that
490 colocalize between type 2 diabetes and osteoarthritis to screen for knockout mice showing
491 phenotypes related to type 2 diabetes or osteoarthritis. The databases used in this scope were the
492 International Mouse Phenotyping Consortium (IMPC) (<https://www.mousephenotype.org/>), Mouse
493 Genome Informatics (MGI) (<http://www.informatics.jax.org/>) and Rat Genome Database (RGD)
494 (<https://rgd.mcw.edu/>) databases. For IMPC and RGD we extracted the knockout mice phenotypes for
495 each potential effector gene using the programmatic data access via their application programming
496 interface (API). For MGI, we used the MGI batch query.

497 For type 2 diabetes, we looked for insulin and diabetes-related phenotypes that included the following
498 terms: insulin, glucose, diabetes, hyperglycaemia, pancreas, pancreatic, obesity, BMI, body weight,
499 body mass, body fat, beta cell, and glucosuria. For osteoarthritis, we looked for musculoskeletal
500 phenotypes including the terms skeletal, muscle, bone, osteo, arthritis, muscular, joint, body size,
501 growth, stature, and height.
502

503 Rare and syndromic human diseases

504 To investigate whether any analysed genes are associated with a monogenic disorder, we extracted
505 data from the Online Mendelian Inheritance in Man (OMIM) (<https://omim.org/>) using their API. The

506 terms we looked up for osteoarthritis-related phenotypes were bone, muscle, skeleton, osteo,
507 arthritis, muscular, joint, body size, growth, skeletal, stature, height, Hand-foot-uterus, synostosis,
508 Martsolf, Warburg, leukodystrophy, squalene, and Finca. For type 2 diabetes we searched for insulin,
509 glycemia, glucose, diabetes, pancreas, pancreatic, obesity, BMI, body weight, body mass, body fat,
510 beta cell, glucosuria, Martsolf, aciduria, Aicardi-Goutières, and Finca.

511

512 Differential gene expression

513 We explored if the analysed genes show differential expression for type 2 diabetes and osteoarthritis
514 using published summary statistics from RNA-seq datasets. For osteoarthritis, differential expression
515 was assessed by comparing paired intact and degraded osteoarthritis cartilage from 124 patients [38].
516 Since the samples were collected within patients, the data is automatically robust against cofactors
517 such as age and population structure. For type 2 diabetes, we used RNA-seq data from surgical
518 pancreatic tissue samples from metabolically phenotyped pancreatectomized patients. Samples were
519 collected from 18 non-diabetic patients and 39 patients that were previously diagnosed with type 2
520 diabetes [39]. The differential expression analysis was based on a linear model with age, sex, and BMI
521 as covariates. We considered genes that changed more than 1.5-fold in either direction and had an
522 adjusted p-value < 0.05 to be differentially expressed between degraded (high-grade) and intact (low-
523 grade) osteoarthritis cartilage, and diabetic versus healthy pancreatic islets, for osteoarthritis and type
524 2 diabetes respectively.

525

526 Multi-trait statistical colocalization analysis with eQTL and pQTL data

527 First, we superimposed molecular QTL information from disease-specific tissues by performing multi-
528 trait molecular QTL-GWAS colocalization analyses. The analyses were performed only on the variants
529 in the 95% credible set. The input consisted of three summary statistics: one from the type 2 diabetes
530 GWAS, one from the osteoarthritis phenotype GWAS, and one from the disease-relevant tissue
531 molecular QTL data set. Since one variant is tested for multiple genes in an eQTL data set, or multiple
532 proteins for the pQTL data sets, we performed the colocalization gene-wise or protein-wise,
533 respectively, such that for each analysis a single molecular QTL summary statistic is available for each
534 variant. If the 95% credible set consisted only of a single variant, for each gene or protein, we included
535 all variants in a 1 Mb window in the analysis.

536 For the multi-trait statistical colocalization analyses, we used the R package *HyPrColoc* (version 1.0.0)
537 [51]. We conducted regional gene-wise analysis to assess whether all traits colocalize by switching off
538 the Bayesian divisive clustering algorithm (`bb.alg=FALSE`). In a similar manner to the *coloc* package, we
539 used *HyPrColoc* to estimate the posterior probabilities and identify candidate causal genes using
540 multiple traits as input. For consistency, evidence for colocalization was considered at a threshold of
541 0.8 for PP4. The type 2 diabetes and osteoarthritis GWAS meta-analyses share five cohorts. Although
542 the sample overlap, we assumed independence between the data sets, as instructed by the
543 developers of the *HyPrColoc* package.

544 Using the prior knowledge that type 2 diabetes and osteoarthritis colocalize in the analysed genomic
545 loci, we adapted the prior parameters of the *HyPrColoc* algorithm accordingly. The first parameter,
546 *prior.1*, which denotes the probability of a SNP being associated with one trait only, was set to $1e-10$,
547 six times smaller than the default. We set the second parameter *prior.2* to 0.7 instead of the default
548 of 0.98. $1-prior.2$ denotes the prior probability of a SNP being associated with an additional trait and
549 $1-(prior.2)^2$ with the SNP being associated with the two other traits. LD between SNPs was again
550 calculated using *plink* (version 2.0 alpha) [49] based on the UK biobank [50].

551

552 Scoring of potential effector genes

553 In genomic loci that colocalized between type 2 diabetes and at least one osteoarthritis phenotype
554 with a PP4 > 0.8, we analysed all genes in a 1 Mb window on either side of the lead variant of the 95%

555 credible set. We incorporated orthogonal multi-omics and functional information to derive a list of
556 high-confidence effector genes for the type 2 diabetes-osteoarthritis comorbidity.

557 Except for the pQTL analysis, all four above-mentioned biological lines of evidence were tested for
558 both osteoarthritis and type 2 diabetes, yielding one separate score for each disease. Additionally, we
559 incorporated information about previously established high-confidence effector genes for the
560 individual diseases. For type 2 diabetes, we defined genes as high-confidence if their top score in the
561 type 2 diabetes knowledge portal was at least 4 (<https://t2d.hugeamp.org/>). For osteoarthritis we
562 selected genes scored as high-confidence by the GO consortium [23]. Since our analysis overlaps with
563 criteria used to define a gene as high-confidence for the individual diseases, we followed an approach
564 to incorporate this information orthogonally: if a gene is high-confidence for a disease, but scored
565 zero in our analysis, we updated the respective disease score to one.

566 We also looked up all variants in the 95% credible sets searching for any missense variants. This look-
567 up was summarized in an additional score, the missense variant score. The total score was defined as
568 the sum of the osteoarthritis score, the type 2 diabetes score, and the missense variant lookup. If,
569 however, for a gene only the missense variant score is non-zero, the total score was set to zero since
570 it is not relevant for the type 2 diabetes-osteoarthritis comorbidity.

571 Based on the scoring of the six orthogonal biological lines of evidence, we defined genes as potential
572 effector genes if they showed at least one line of evidence for either one of the diseases. Genes that
573 scored at least one line of evidence for osteoarthritis and one for type 2 diabetes were defined as
574 likely effector genes for the comorbidity. High-confidence effector genes were a subset of the likely
575 effector genes that scored at least 3 in the total score (Table S3).

576 To further analyse our set of effector genes, we grouped them according to the osteoarthritis
577 localisation. If a gene is only associated with osteoarthritis at any site, knee and/or hip osteoarthritis
578 and TJR, then it was considered to be associated with both knee and hip osteoarthritis. If, in addition,
579 an association with knee and/or TKR is observed, then we consider the gene to be mostly associated
580 with knee osteoarthritis. Similarly, if it is associated with hip or THR, then the gene is classified as
581 mostly related to hip osteoarthritis.

582

583 [Multi-trait statistical colocalization analysis with adiposity measures](#)

584 In the genomic regions that colocalized between type 2 diabetes and osteoarthritis, we performed
585 multi-trait colocalization analyses between type 2 diabetes, osteoarthritis and the above-mentioned
586 measures of adiposity. The analyses were performed only on the variants in the 95% credible set. If
587 the 95% credible set consisted only of a single variant, for each gene or protein, we included all
588 variants in a 1 Mb window on either side of the single variant in the analysis. As for the molecular QTL
589 colocalization, we used the same functions of the R package *HyPrColoc* (version 1.0.0) and adjusted
590 the prior parameters accordingly ($prior.1=1e-10$, $prior.2=0.7$) [51]. For consistency, evidence for
591 colocalization was considered at a threshold of 0.8 for PP4.

592

593 [Pathway analysis](#)

594 We performed gene set enrichment analyses on the likely and on the high-confidence effector genes
595 stratified by knee or hip osteoarthritis association (Table S5). The number of genes in each set is
596 summarized in Table 2. We used the human resources and the enrichment software from the
597 ConsensusPathDB (<http://cpdb.molgen.mpg.de/>) to examine the functional annotation of each gene
598 set by testing their enrichment among curated networks in humans [52]. We used the networks from
599 Reactome, KEGG, WikiPathways and Gene Ontology. For the latter, we included the subcategories
600 molecular function, biological processes, and cellular component up to level 4. We required a
601 minimum overlap of 2 genes for enrichment. The significance threshold was set at $FDR < 0.05$.

602

Gene set	Number of genes
Likely effector genes	72
Likely effector genes related to knee	67
Likely effector genes related to hip	43
HC effector genes	19
HC effector genes related to knee	18
HC effector genes related to hip	10

Table 2: number of genes in each gene set (HC =high-confidence)

603

604 [Druggable genome](#)

605 To outline drug repurposing targets, we queried the druggability status of the 72 likely effector genes
606 for the comorbidity. We used the Druggable Genome database, which consists of 4479 genes that are
607 classified into three tiers depending on their progress in the drug development pipeline [15]. Tier 1
608 included 1427 genes that are clinical-phase drug candidates or targets of already approved small
609 molecules and biotherapeutic drugs. Tier 2 consisted of 682 genes that encode targets with known
610 bioactive drug-like small-molecule binding partners and genes with $\geq 50\%$ identity (over $\geq 75\%$ of the
611 sequence) with approved drug targets. Tier 3 comprised 2370 genes encoding secreted or extracellular
612 proteins, proteins with more distant similarity to approved drug targets, and members of key
613 druggable gene families that were not included in tier 1 or 2. Tier 3 was further subdivided to prioritize
614 genes in proximity (+50 kbp) to a GWAs SNP from the GWAS catalog and had an extracellular location
615 (Tier 3A). Tier 3B is composed of the remaining genes.

616 For the likely effector genes included in tier 1, we further examined the approved or in clinical trial
617 drugs using the DrugBank online database (<https://www.drugbank.com>, accessed on the 1st of August
618 2022).

619 [Causal inference analysis](#)

620 Causal inference was strengthened through use of bi-directional two-sample Mendelian
621 randomization (MR) between type 2 diabetes and all analysed osteoarthritis phenotypes [10]. We
622 used the *TwoSampleMR* R package (version 0.5.6), which is curated by MR-Base [53]. We performed
623 causal inference analyses on the full summary statistics (Table S6). For all analyses, instrumental
624 variables (IVs) were selected as the genome-wide significant ($p\text{-value} \leq 5 \times 10^{-8}$) and independent
625 SNPs from the full data. Independence was defined as LD-based clumped SNPs with a strict LD
626 threshold of $R^2 = 0.001$ over a 10Mb window on either side of the index variant. To assure that the
627 IVs are more strongly related to the exposure than to the outcome, we applied Steiger filtering [10].
628 We applied the inverse variance weighted (IVW) method, which performs a random-effects meta-
629 analysis of the Wald ratios for each SNP and the weighted median (WM) method. Finally, we
630 performed sensitivity analyses by testing for heterogeneity based on the Q-statistic using the
631 *mr_heterogeneity* function from the *TwoSampleMR* R package. Horizontal pleiotropy was assessed
632 through the intercept of the MR-Egger regression. To account for multiple testing, p-values were
633 adjusted using the false discovery rate (FDR) approach [10].

634

635 [Two-step Mendelian randomization](#)

636 We performed a two-step Mendelian randomization analysis between different adiposity measures
637 and type 2 diabetes or osteoarthritis using *cis* expression QTLs (eQTLs) of each high-confidence
638 effector gene in disease-relevant tissues as mediators (Table S7) [55]. In the first step, we assess
639 whether adiposity is causal for the expression of our genes in the respective analysed tissues. To
640 assure independence of IVs between the two steps, we excluded independent eQTLs from the risk
641 variants of each adiposity measure. Independence was defined by local LD-based clumping with $R^2 =$
642 0.001 over a 10Mb window on either side of the index variant.

643 For the second step, we used independent genetics variants associated to each high-confidence gene
644 as IVs and conducted a two-sample MR analysis between each of our genes and type 2 diabetes or
645 osteoarthritis. For each analysed tissue and each gene-disease pair, we conducted one MR analysis
646 using the *TwoSampleMR* R package (version 0.5.6) [53]. If only one SNP was available after clumping
647 and harmonizing the data, we employed the Wald ratio method. If more than one SNP remained after
648 the pre-processing steps, we applied the IVW method and tested for heterogeneity with the
649 *mr_heterogeneity* function. Moreover, if more than three SNPs were used for the causal inference
650 analysis, we also tested for horizontal pleiotropy through MR-Egger regression. Additionally, we
651 estimated the F-statistics from summary level data as $mean(beta^2/se^2)$ to assess the strength of the
652 IVs [10]. Finally, we adjusted the p-values for multiple testing using the FDR approach.

653 Tissue fractionation

654 We determined the tissue-specific role of BMI in both osteoarthritis and type 2 diabetes using MR
655 restricted to BMI instruments colocalizing with eQTLs in brain and adipose tissue, respectively, as
656 described in [22] (Table S10). Briefly, summary-level MR was performed restricted to the 86 adipose
657 tissue colocalizing SNPs and the 140 brain tissue colocalizing SNPs, where the numerator of the Wald
658 ratio is the SNP effect on osteoarthritis or type 2 diabetes and the denominator is the effect estimate
659 for the SNP on BMI from a GWAS meta-analysis of UK Biobank and the GIANT consortium [56] available
660 at the MR-Base platform [53]. Osteoarthritis summary statistics were extracted from the latest GWAS
661 of hip and knee osteoarthritis from the GO consortium [23]. Type 2 diabetes summary statistics were
662 extracted from the latest European DIAMANTE consortium GWAS [36].

663 We used inverse variance weighted meta-analysis of the individual SNP Wald ratios to estimate the
664 causal effects of adipose tissue-instrumented BMI and brain tissue-instrumented BMI on each
665 outcome. As sensitivity analyses, we performed MR-Egger to determine the potential role of
666 pleiotropic effects (i.e. mediated via BMI-independent pathways), which gives a pleiotropy robust
667 estimate of the causal effect assuming that there is no correlation between instrument strength (i.e.
668 the association of the SNP with BMI) and the pleiotropic effect [10]. We also performed weighted
669 median analysis, which gives an unbiased estimate of the causal effect as long as less than 50% of the
670 SNPs are invalid instruments [57]. We performed a z-test to assess the effect difference between
671 adipose and brain tissue-instrumented BMI MR analyses.

672 Supplemental information titles

673 **Table S1:** Genetic correlation matrix for type 2 diabetes and osteoarthritis.

674 **Table S2:** Overview of colocalized genomic loci between type 2 diabetes and osteoarthritis with
675 additional information about colocalization with molecular QTLs from disease-relevant tissues.

676 **Table S3A:** Scoring of all genes in a 1Mb window on either side of the lead variant of the 18
677 colocalized regions between type 2 diabetes and osteoarthritis.

678 **Table S3B:** Overview of scoring of likely effector genes for the type 2 diabetes and osteoarthritis
679 comorbidity.

680 **Table S3C:** Overview of scoring of high confidence effector genes for the type 2 diabetes and
681 osteoarthritis comorbidity.

682 **Table S4:** Likely effector genes for the type 2 diabetes and osteoarthritis comorbidity included in the
683 druggable genome.

- 684 **Table S5A:** Results of the pathway analyses of the high confidence effector genes for the type 2
685 diabetes-osteoarthritis comorbidity stratified by knee or hip association.
- 686 **Table S5B:** Results of the pathway analyses of the likely effector genes for the type 2 diabetes-
687 osteoarthritis comorbidity stratified by knee or hip association.
- 688 **Table S6A:** Results of bidirectional two-sample Mendelian randomization analyses between type 2
689 diabetes and osteoarthritis.
- 690 **Table S6B:** Steiger-filtered results of bidirectional two-sample Mendelian randomization analyses
691 between type 2 diabetes and osteoarthritis.
- 692 **Table S7A:** First step results of two-step Mendelian randomization analysis between adiposity
693 measures and gene expression of high confidence effector genes for the type 2 diabetes and
694 osteoarthritis comorbidity in disease-relevant tissues.
- 695 **Table S7B:** Second step results of two-step Mendelian randomization analysis between gene
696 expression of high confidence effector genes for the type 2 diabetes and osteoarthritis comorbidity
697 in disease-relevant tissues and either one of the diseases.
- 698 **Table S9A:** Multi-trait colocalization between type 2 diabetes, osteoarthritis and BMI for regions that
699 colocalized between type 2 diabetes and osteoarthritis.
- 700 **Table S9B:** Direction of effect and p-value of variants in the 95% credible set of the colocalized
701 regions for the comorbidity.
- 702 **Table S10:** Results of two-sample Mendelian randomization analyses between type 2 diabetes or
703 osteoarthritis and BMI risk variants associated with eQTLs in brain and subcutaneous adipose tissue.
704

705 References

- 706 [1] K. Nicholson, T. T. Makovski, L. E. Griffith, P. Raina, S. Stranges, and M. van den Akker,
707 “Multimorbidity and comorbidity revisited: refining the concepts for international health
708 research,” *Journal of Clinical Epidemiology*, vol. 105. Elsevier USA, pp. 142–146, Jan. 01, 2019.
709 doi: 10.1016/j.jclinepi.2018.09.008.
- 710 [2] H. Nguyen, G. Manolova, C. Daskalopoulou, S. Vitoratou, M. Prince, and A. M. Prina,
711 “Prevalence of multimorbidity in community settings: A systematic review and meta-analysis
712 of observational studies”, doi: 10.1177/2235042X19870934.
- 713 [3] D. L. Bezerra de Souza *et al.*, “Multimorbidity and its associated factors among adults aged 50
714 and over: A cross-sectional study in 17 European countries,” *PLoS One*, vol. 16, no. 2, p.
715 e0246623, Feb. 2021, doi: 10.1371/JOURNAL.PONE.0246623.
- 716 [4] M. F. Williams, D. A. London, E. M. Husni, S. Navaneethan, and S. R. Kashyap, “Type 2
717 diabetes and osteoarthritis: A systematic review and meta-analysis,” *Journal of Diabetes and
718 its Complications*, vol. 30, no. 5. Elsevier Inc., pp. 944–950, Jul. 01, 2016. doi:
719 10.1016/j.jdiacomp.2016.02.016.
- 720 [5] M. Sandoval-Rosario *et al.*, “Prevalence of Arthritis Among Adults with Prediabetes and
721 Arthritis-Specific Barriers to Important Interventions for Prediabetes — United States, 2009–
722 2016,” *MMWR Morb Mortal Wkly Rep*, vol. 67, no. 44, pp. 1238–1241, Nov. 2019, doi:
723 10.15585/MMWR.MM6744A4.

- 724 [6] T. Vos *et al.*, “Global burden of 369 diseases and injuries in 204 countries and territories,
725 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019,” *The Lancet*,
726 vol. 396, pp. 1204–1222, 2020, doi: 10.1016/S0140-6736(20)30925-9.
- 727 [7] J. Martel-Pelletier *et al.*, “Osteoarthritis,” *Nature Reviews Disease Primers 2016 2:1*, vol. 2, no.
728 1, pp. 1–18, Oct. 2016, doi: 10.1038/nrdp.2016.72.
- 729 [8] N. Veronese *et al.*, “Type 2 diabetes mellitus and osteoarthritis Europe PMC Funders Group”,
730 doi: 10.1016/j.semarthrit.2019.01.005.
- 731 [9] K. Louati, C. Vidal, F. Berenbaum, and J. Sellam, “Association between diabetes mellitus and
732 osteoarthritis: Systematic literature review and meta-analysis,” *RMD Open*, vol. 1, no. 1. BMJ
733 Publishing Group, p. e000077, Jan. 01, 2015. doi: 10.1136/rmdopen-2015-000077.
- 734 [10] E. Sanderson *et al.*, “Mendelian randomization,” *Nature Reviews Methods Primers 2022 2:1*,
735 vol. 2, no. 1, pp. 1–21, Feb. 2022, doi: 10.1038/s43586-021-00092-5.
- 736 [11] Z. Cui, H. Feng, B. He, Y. Xing, Z. Liu, and Y. Tian, “Type 2 Diabetes and Glycemic Traits Are Not
737 Causal Factors of Osteoarthritis: A Two-Sample Mendelian Randomization Analysis,” *Front*
738 *Genet*, vol. 0, p. 1726, Jan. 2021, doi: 10.3389/FGENE.2020.597876.
- 739 [12] E. Zengini *et al.*, “Genome-wide analyses using UK Biobank data provide insights into the
740 genetic architecture of osteoarthritis,” *Nat Genet*, vol. 50, no. 4, pp. 549–558, Apr. 2018, doi:
741 10.1038/s41588-018-0079-y.
- 742 [13] M. v. Holmes *et al.*, “Causal effects of body mass index on cardiometabolic traits and events:
743 A Mendelian randomization analysis,” *Am J Hum Genet*, vol. 94, no. 2, pp. 198–208, Feb.
744 2014, doi: 10.1016/j.ajhg.2013.12.014.
- 745 [14] A. Khor, C. A. Ma, C. Hong, L. L. Y. Hui, and Y. Y. Leung, “Diabetes mellitus is not a risk factor
746 for osteoarthritis,” *RMD Open*, vol. 6, no. 1, p. e001030, Feb. 2020, doi: 10.1136/RMDOPEN-
747 2019-001030.
- 748 [15] C. Finan *et al.*, “The druggable genome and support for target identification and validation in
749 drug development,” *Sci Transl Med*, vol. 9, no. 383, Mar. 2017, doi:
750 10.1126/SCITRANSLMED.AAG1166/SUPPL_FILE/AAG1166_TABLE_S1.ZIP.
- 751 [16] J. P. Frías, “Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
752 like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes,”
753 *Expert Rev Endocrinol Metab*, vol. 15, no. 6, pp. 379–394, Nov. 2020, doi:
754 10.1080/17446651.2020.1830759.
- 755 [17] S. Braselmann *et al.*, “R406, an orally available spleen tyrosine kinase inhibitor blocks fc
756 receptor signaling and reduces immune complex-mediated inflammation,” *J Pharmacol Exp*
757 *Ther*, vol. 319, no. 3, pp. 998–1008, 2006, doi: 10.1124/JPET.106.109058.
- 758 [18] Y. Tanaka, D. Millson, S. Iwata, and S. Nakayamada, “Safety and efficacy of fostamatinib in
759 rheumatoid arthritis patients with an inadequate response to methotrexate in phase II
760 OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study,” *Rheumatology*, vol. 60, no. 6, pp. 2884–2895, Jun.
761 2021, doi: 10.1093/RHEUMATOLOGY/KEAA732.
- 762 [19] L. Ray, P. Chin, and K. Miotto, “Naltrexone for the treatment of alcoholism: clinical findings,
763 mechanisms of action, and pharmacogenetics,” *CNS Neurol Disord Drug Targets*, vol. 9, no. 1,
764 pp. 13–22, Jun. 2010, doi: 10.2174/187152710790966704.

- 765 [20] I. J. Onakpoya, J. J. Lee, K. R. Mahtani, J. K. Aronson, and C. J. Heneghan, "Naltrexone–
766 bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of
767 unpublished clinical study reports," *Br J Clin Pharmacol*, vol. 86, no. 4, pp. 646–667, Apr.
768 2020, doi: 10.1111/BCP.14210.
- 769 [21] B. R. Gauthier *et al.*, "Thyroid hormones in diabetes, cancer, and aging," *Aging Cell*, vol. 19,
770 no. 11, p. e13260, Nov. 2020, doi: 10.1111/ACEL.13260.
- 771 [22] G. M. Leyden *et al.*, "Harnessing tissue-specific genetic variation to dissect putative causal
772 pathways between body mass index and cardiometabolic phenotypes," *The American Journal*
773 *of Human Genetics*, vol. 109, pp. 240–252, 2022, doi: 10.1016/j.ajhg.2021.12.013.
- 774 [23] C. G. Boer *et al.*, "Deciphering osteoarthritis genetics across 826,690 individuals from 9
775 populations," *Cell*, Aug. 2021, doi: 10.1016/J.CELL.2021.07.038.
- 776 [24] S. Boissel *et al.*, "Loss-of-Function Mutation in the Dioxygenase-Encoding FTO Gene Causes
777 Severe Growth Retardation and Multiple Malformations," *Am J Hum Genet*, vol. 85, no. 1, pp.
778 106–111, Jul. 2009, doi: 10.1016/J.AJHG.2009.06.002/ATTACHMENT/64B765DE-D8B9-46E8-
779 BBE3-45057DED616B/MMC1.PDF.
- 780 [25] S. Smemo *et al.*, "Obesity-associated variants within FTO form long-range functional
781 connections with IRX3," *Nature*, vol. 507, no. 7492, pp. 371–375, Mar. 2014, doi:
782 10.1038/nature13138.
- 783 [26] A. Hartley *et al.*, "Using multivariable Mendelian randomization to estimate the causal effect
784 of bone mineral density on osteoarthritis risk, independently of body mass index," *Int J*
785 *Epidemiol*, vol. 2021, pp. 1–14, Dec. 2021, doi: 10.1093/IJE/DYAB251.
- 786 [27] L. del Bosque-Plata, E. Martínez-Martínez, M. Á. Espinoza-Camacho, and C. Gragnoli, "The
787 Role of TCF7L2 in Type 2 Diabetes," *Diabetes*, vol. 70, no. 6, pp. 1220–1228, Jun. 2021, doi:
788 10.2337/DB20-0573.
- 789 [28] J. S. Rockel *et al.*, "Hedgehog inhibits β -catenin activity in synovial joint development and
790 osteoarthritis," *J Clin Invest*, vol. 126, no. 5, pp. 1649–1663, May 2016, doi:
791 10.1172/JCI80205.
- 792 [29] T. Jin, "Current Understanding on Role of the Wnt Signaling Pathway Effector TCF7L2 in
793 Glucose Homeostasis," *Endocr Rev*, vol. 37, no. 3, pp. 254–277, Jun. 2016, doi:
794 10.1210/ER.2015-1146.
- 795 [30] A. B. Blom, P. L. van Lent, P. M. van der Kraan, and W. B. van den Berg, "To Seek Shelter from
796 the Wnt in Osteoarthritis? Wnt-Signaling as a Target for Osteoarthritis Therapy," *Curr Drug*
797 *Targets*, vol. 11, no. 5, pp. 620–629, Mar. 2010, doi: 10.2174/138945010791011901.
- 798 [31] A. Mahajan *et al.*, "Refining the accuracy of validated target identification through coding
799 variant fine-mapping in type 2 diabetes," *Nat Genet*, vol. 50, no. 4, p. 559, Apr. 2018, doi:
800 10.1038/S41588-018-0084-1.
- 801 [32] J. Taneera *et al.*, "Identification of novel genes for glucose metabolism based upon expression
802 pattern in human islets and effect on insulin secretion and glycemia," *Hum Mol Genet*, vol.
803 24, no. 7, pp. 1945–1955, Apr. 2015, doi: 10.1093/HMG/DDU610.

- 804 [33] K. Mizuhashi *et al.*, “OBIF, an osteoblast induction factor, plays an essential role in bone
805 formation in association with osteoblastogenesis,” *Dev Growth Differ*, vol. 54, no. 4, pp. 474–
806 480, May 2012, doi: 10.1111/J.1440-169X.2012.01333.X.
- 807 [34] S. I. Harada and G. A. Rodan, “Control of osteoblast function and regulation of bone mass,”
808 *Nature 2003 423:6937*, vol. 423, no. 6937, pp. 349–355, May 2003, doi:
809 10.1038/nature01660.
- 810 [35] N. Maruotti, A. Corrado, and F. P. Cantatore, “Osteoblast role in osteoarthritis pathogenesis,”
811 *J Cell Physiol*, vol. 232, no. 11, p. 2957, Nov. 2017, doi: 10.1002/JCP.25969.
- 812 [36] A. Mahajan *et al.*, “Fine-mapping type 2 diabetes loci to single-variant resolution using high-
813 density imputation and islet-specific epigenome maps,” *Nat Genet*, vol. 50, no. 11, pp. 1505–
814 1513, Nov. 2018, doi: 10.1038/s41588-018-0241-6.
- 815 [37] A. I. Hernandez Cordero *et al.*, “Genome-wide Associations Reveal Human-Mouse Genetic
816 Convergence and Modifiers of Myogenesis, CPNE1 and STC2,” *The American Journal of*
817 *Human Genetics*, vol. 105, no. 6, pp. 1222–1236, Dec. 2019, doi:
818 10.1016/J.AJHG.2019.10.014.
- 819 [38] G. Katsoula *et al.*, “A molecular map of long non-coding RNA expression, isoform switching
820 and alternative splicing in osteoarthritis,” *Hum Mol Genet*, vol. 00, pp. 1–16, Jan. 2022, doi:
821 10.1093/HMG/DDAC017.
- 822 [39] L. Wigger *et al.*, “Multi-omics profiling of living human pancreatic islet donors reveals
823 heterogeneous beta cell trajectories towards type 2 diabetes,” *Nature Metabolism 2021 3:7*,
824 vol. 3, no. 7, pp. 1017–1031, Jun. 2021, doi: 10.1038/s42255-021-00420-9.
- 825 [40] D. Ochoa, M. Karim, M. Ghossaini, D. G. Hulcoop, E. M. McDonagh, and I. Dunham, “Human
826 genetics evidence supports two-thirds of the 2021 FDA-approved drugs.,” *Nat Rev Drug*
827 *Discov*, Jul. 2022, doi: 10.1038/D41573-022-00120-3.
- 828 [41] Z. Fewell, G. Davey Smith, and J. A. C. Sterne, “The impact of residual and unmeasured
829 confounding in epidemiologic studies: a simulation study,” *Am J Epidemiol*, vol. 166, no. 6, pp.
830 646–655, Sep. 2007, doi: 10.1093/AJE/KWM165.
- 831 [42] A. K. Picke, G. Campbell, N. Napoli, L. C. Hofbauer, and M. Rauner, “Update on the impact of
832 type 2 diabetes mellitus on bone metabolism and material properties,” *Endocr Connect*, vol.
833 8, no. 3, p. R55, 2019, doi: 10.1530/EC-18-0456.
- 834 [43] A. D. Berendsen and B. R. Olsen, “Osteoblast-adipocyte lineage plasticity in tissue
835 development, maintenance and pathology,” *Cell Mol Life Sci*, vol. 71, no. 3, pp. 493–497, Feb.
836 2014, doi: 10.1007/S00018-013-1440-Z.
- 837 [44] J. Steinberg *et al.*, “A molecular quantitative trait locus map for osteoarthritis,” *Nature*
838 *Communications 2021 12:1*, vol. 12, no. 1, pp. 1–11, Feb. 2021, doi: 10.1038/s41467-021-
839 21593-7.
- 840 [45] A. Viñuela, “Genetic variant effects on gene expression in human pancreatic islets and their
841 implications for T2D”, doi: 10.1038/s41467-020-18581-8.
- 842 [46] B. K. Bulik-Sullivan *et al.*, “LD Score regression distinguishes confounding from polygenicity in
843 genome-wide association studies,” *Nature Genetics 2015 47:3*, vol. 47, no. 3, pp. 291–295,
844 Feb. 2015, doi: 10.1038/ng.3211.

- 845 [47] A. Auton *et al.*, “A global reference for human genetic variation,” *Nature* 2015 526:7571, vol.
846 526, no. 7571, pp. 68–74, Sep. 2015, doi: 10.1038/nature15393.
- 847 [48] C. Giambartolomei *et al.*, “Bayesian Test for Colocalisation between Pairs of Genetic
848 Association Studies Using Summary Statistics,” *PLoS Genet*, vol. 10, no. 5, p. e1004383, May
849 2014, doi: 10.1371/journal.pgen.1004383.
- 850 [49] S. Purcell *et al.*, “PLINK: A Tool Set for Whole-Genome Association and Population-Based
851 Linkage Analyses,” *The American Journal of Human Genetics*, vol. 81, no. 3, pp. 559–575, Sep.
852 2007, doi: 10.1086/519795.
- 853 [50] C. Bycroft *et al.*, “The UK Biobank resource with deep phenotyping and genomic data,”
854 *Nature*, vol. 562, no. 7726, pp. 203–209, 2018.
- 855 [51] C. N. Foley *et al.*, “A fast and efficient colocalization algorithm for identifying shared genetic
856 risk factors across multiple traits,” *Nat Commun*, vol. 12, no. 1, p. 764, Dec. 2021, doi:
857 10.1038/s41467-020-20885-8.
- 858 [52] A. Kamburov, K. Pentchev, H. Galicka, C. Wierling, H. Lehrach, and R. Herwig,
859 “ConsensusPathDB: toward a more complete picture of cell biology,” *Nucleic Acids Res*, vol.
860 39, no. suppl_1, pp. D712–D717, Jan. 2011, doi: 10.1093/NAR/GKQ1156.
- 861 [53] G. Hemani *et al.*, “The MR-base platform supports systematic causal inference across the
862 human phenome,” *Elife*, vol. 7, May 2018, doi: 10.7554/ELIFE.34408.
- 863 [54] S. L. Pulit *et al.*, “Meta-analysis of genome-wide association studies for body fat distribution
864 in 694 649 individuals of European ancestry,” *Hum Mol Genet*, vol. 28, no. 1, pp. 166–174,
865 Jan. 2019, doi: 10.1093/HMG/DDY327.
- 866 [55] C. L. Relton and G. Davey Smith, “Two-step epigenetic Mendelian randomization: a strategy
867 for establishing the causal role of epigenetic processes in pathways to disease,” *Int J*
868 *Epidemiol*, vol. 41, no. 1, pp. 161–176, Feb. 2012, doi: 10.1093/IJE/DYR233.
- 869 [56] L. Yengo *et al.*, “Meta-analysis of genome-wide association studies for height and body mass
870 index in ~700000 individuals of European ancestry,” *Hum Mol Genet*, vol. 27, no. 20, pp.
871 3641–3649, Oct. 2018, doi: 10.1093/HMG/DDY271.
- 872 [57] J. Bowden, G. Davey Smith, P. C. Haycock, and S. Burgess, “Consistent Estimation in
873 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
874 Estimator,” *Genet Epidemiol*, vol. 40, no. 4, pp. 304–314, May 2016, doi: 10.1002/GEPI.21965.
- 875
- 876
- 877
- 878